Mutated Nanobody Biosensor for Rapid Viral Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current viral biosensors are inadequate for rapid, specific, and cost-effective detection of viral targets, particularly during pandemics, due to batch-to-batch inconsistencies and long analysis times, which limits their ability to manage outbreaks effectively.
Innovation Solution
A portable electrochemical biosensor using mutated nanobodies with a cysteine mutation in the FR1 region for surface immobilization, allowing correct orientation and direct grafting onto conductive surfaces for rapid and specific target detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibodies are used for biosensor immobilization, then target detection capability is achieved, but batch-to-batch inconsistency and extensive production time occur
Solution Approach 1:
The patent uses nanobodies instead of conventional antibodies, which can be rapidly produced through recombinant technology in bacterial systems. This replaces the need for time-consuming monoclonal antibody production and eliminates batch-to-batch variability inherent in polyclonal antibodies, achieving consistent detection results with much shorter production timelines.
Solution Approach 2:
The patent introduces cysteine mutations at specific positions (K13C, F36C, L47C) in the nanobody framework regions to enable thiol-based immobilization chemistry. This parameter change in the amino acid sequence allows for controlled orientation and consistent attachment to the electrode surface, ensuring reliable detection across multiple biosensor batches.
2Ease of manufacture
If chemical functionalization with self-assembled monolayers is used for nanobody immobilization, then surface attachment is achieved, but time-consuming multi-step process occurs
Solution Approach 1:
The patent extracts the immobilization function from complex multi-step chemical functionalization processes and integrates it directly into the nanobody structure through cysteine mutations. This allows direct thiol-gold or thiol-carbon chemistry without requiring separate self-assembled monolayer formation steps, dramatically simplifying the manufacturing process.
Solution Approach 2:
The cysteine-containing nanobodies self-immobilize onto the conductive surface through their thiol groups, eliminating the need for external functionalization agents or complex chemical treatments. The nanobody itself provides the chemical functionality needed for attachment, making the process self-service and highly efficient.
3Speed
If rapid detection is implemented, then response time is reduced, but detection precision and specificity may be compromised
Solution Approach 1:
The patent segments the antibody structure into single-domain nanobodies that can be independently optimized. This allows the binding region (CDR loops) to be specifically designed for high affinity and specificity to the target antigen, while the framework regions are engineered for stability and rapid immobilization, achieving both speed and precision simultaneously.
Solution Approach 2:
The patent replaces complex mechanical/chemical immobilization systems with direct thiol-based covalent bonding. This substitution enables rapid, irreversible attachment of nanobodies to the electrode surface, creating a stable sensor that maintains high detection specificity while achieving fast response times.
4Ease of operation
If nanobody orientation is not optimized, then immobilization is simplified, but target recognition capability is reduced
Solution Approach 1:
The patent introduces asymmetric cysteine mutations at specific positions (K13C, F36C, L47C) in the nanobody framework regions, which are spatially distant from the antigen-binding CDR loops. This asymmetric placement ensures that when the nanobody attaches to the electrode surface through the cysteine thiol, the antigen-binding site is oriented away from the surface, maintaining full recognition capability while simplifying immobilization.
Solution Approach 2:
The cysteine residue acts as an intermediary between the nanobody and the electrode surface. By placing the cysteine at a strategic position in the framework region, it mediates the attachment process while leaving the antigen-binding CDR loops free to interact with the target, ensuring both ease of immobilization and reliable target recognition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mutated nanobody-based biosensor enables rapid, sensitive, and cost-effective detection of viral targets, such as SARS-CoV-2, with improved specificity and reduced false negatives, surpassing the limitations of existing methods like RT-PCR.
Implementation Method 1
an amino acid present in the loop of the FR1 region of the framework, preferably at position 12, 13, 14 or 15, is mutated to cysteine
Data Source
AI summary
The present invention relates to methods for detecting a target in a sample using mutated nanobodies, wherein an amino acid present in the loop of the FR1 region of framework of the nanobodies is mutated to cysteine.